Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: A review

Journal of Diabetes and its Complications

Volumn 24, Issue 5, 2010, Pages 354-360

  Schemmel, Kate E ^a   Padiyara, Rosalyn S ^b   D'Souza, Jennifer J ^b  

^a Inpatient Pharmacy   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Aldose reductase inhibitor(s); Diabetes; Peripheral neuropathy

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ALRESTATIN; EPALRESTAT; FIDARESTAT; INSULIN; POLYOL; RANIRESTAT; SORBINAL; TOLRESTAT; UNCLASSIFIED DRUG; ZENARESTAT; ZOPOLRESTAT;

ADULT; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ELECTROPHYSIOLOGY; HUMAN; MEDLINE; NERVE CONDUCTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW;

ALDEHYDE REDUCTASE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLIDINES; MULTICENTER STUDIES AS TOPIC; NEURAL CONDUCTION; POLYMERS; PYRAZINES; RHODANINE; SPIRO COMPOUNDS; THIAZOLIDINES; UNITED STATES;

EID: 77956227831     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2009.07.005     Document Type: Review

References (26)

1. Asano T., Saito Y., and Kawakami M. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860) Journal of Diabetes and its Complications 18 2004 336 342
2. Bril V., Buchanan R.A. The AS-3201 Study Group Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy Diabetes Care 27 2004 2369 2374
3. Bril V., Buchanan R.A. The Ranirestat Study Group Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy Diabetes Care 29 2006 68 72
4. Brownlee M., Aiello L.P., and Cooper M.E. Complications of diabetes mellitus H.M. Kronenberg, S. Melmed, K.S. Polonsky, P.R. Larsen, Williams textbook of endocrinology 11th ed. 2008 Saunders Philadelphia Accessed electronically July 10, 2008
5. DeJong R.N. Disease of the peripheral nerves R.N. DeJong, The neurologic examination 3rd ed 1967 Hoeber New York NY 750 772
6. DeJong R.N. The electrical examination RN DeJong, The neurologic examination 3rd ed. 1967 Hoeber Medical Division, Harper & Row New York NY 568 581
7. Epalrestat SC Sweetman, Martindale - the complete drug reference 35th ed. 2007 Pharmaceutical Press London 398
8. Goto Y., Hotta N., and Shigeta Y. A placebo-controlled double blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy Diabetic Medicine 10 Suppl 2 1993 39S 43S
9. Hotta N., Akanuma, and Kawamori R. Long-term clinical effects of epalrestat, an aldose reductase inhibitor on diabetic peripheral neuropathy Diabetes Care 29 2006 1538 1544
10. Hotta N., Sakamoto N., and Shigeta Y. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study Journal of Diabetes and its Complications 10 1996 168 172
11. Hotta N., Toyota T., and Matsuoka K. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy Diabetes Care 24 2001 1776 1782
12. Ikeda T., Iwata K., and Tanaka Y. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus Diabetes Research and Clinical Practice 43 1999 193 198
13. Micromedex Healthcare Series, (electronic version). Thomson Micromedex, Greenwood Village, Colorado, USA. Available at: http://www.thomsonhc.com (accessed 2008 Apr 1).
14. Nakayama M., Nakamura J., and Hamada Y. Aldose reductase inhibition ameliorates pupillary light reflex and f-wave latency in patients with mild diabetic neuropathy Diabetes Care 24 2001 1093 1098
15. National Diabetes Information Clearinghouse A service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH. NIH Publication No. 08-3892 2009 http://diabetes.niddk.nih.gov/DM/PUBS/statistics/ #y-people Bethesda, MD; last updated June 2008. Accessed at June 17, 2009
16. Niemark M.A., and Kong X. Signal processing methods for automatic F-wave latency assignment Advanced Medical Signal Infomation Process 2000 290 296
17. Oka M., and Kato N. Aldose reductase inhibitors Journal of Enzyme Inhibition 16 2001 465 473
18. Oyama T., Miyasita Y., and Watanabe H. The role of polyol pathway in high glucose-induced endothelial cell damages Diabetes Research and Clinical Practice 73 2006 227 234
19. Perkins B.A., and Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods Clinical Neurophysiology 114 2003 1167 1175
20. Pleasure D.E., and Schotland D.L. Acquired neuropathies L.P. Rowland, Merritt's textbook of neurology 8th ed 1989 Lea & Febiger Malvern, PA 614 615
21. Roberts C.S., Gleis G.E., and Seligson D. General principles: diagnosis and treatment of complications: nerve conduction studies BD Browner, JB Jupiter, AM Levine, PG Trafton, Browner: skeletal trauma: basic science, management, and reconstruction 3rd ed. 2003 Saunders Philadelphia Accessed electronically July 10, 2008
22. Rowland L.P. Identifying disorders of the motor unit LP Rowland, Merritt's textbook of neurology 8th ed 1989 Lea & Febiger Malvern, PA 707 709
23. Steele J.W., Faulds D., and Goa K.L. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus Drugs & Aging 3 1993 532 535
24. Triplitt C.L., Reasner C.A., and Isley W.L. Diabetes mellitus J.T. DiPirio, R.L. Talbert, G.C. Yee, et. al, Pharmacotherapy: a pathophysiologic approach 6th ed 2005 McGraw Hill New York, NY 1361
25. Uchida K. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin dependent diabetes mellitus Clinical Therapeutics 17 1995 460 466
26. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain Diabetes Care 31 Suppl 2 2008 255 261